- Regenerative medicine company AVITA Medical (AVH) confirms partnership with Premier Inc to supply the company’s RECELL system to 4,440 US hospitals and health systems within Premier’s network
- The agreement allows Premier members to take advantage of a special pricing and terms pre-negotiated by Premier for treating adult and pediatric patients that require treatment for severe burns
- The partnership comes shortly after AVITA had received FDA approval for its premarket approval application
- AVITA’s share price was up 5.25 per cent, trading at $3.21 per share by the end of the trading day
Regenerative medicine company AVITA Medical (AVH) has confirmed a partnership with Premier Inc to supply the company’s RECELL system to hospitals across the US.
The partnership is said to ensure timely access to the RECELL system for about 4,440 US hospitals and health systems within Premier’s network.
The agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for the treatment of adult and pediatric patients that require treatment for severe burns.
“When someone experiences a severe burn injury, time matters, and that is why this agreement with Premier is so important – it will help ensure that patients in need of treatment are able to efficiently and effectively access the RECELL System without delay,” said AVITA Medical’s Chief Executive Officer Mike Perry.
“As a leading GPO, Premier is a trusted partner among their alliance of members and AVITA Medical is committed to building on that trust by providing quality products to help ensure the best patient care possible.
“This agreement represents a major milestone for AVITA Medical as it puts our innovative RECELL System into the hands of those caring for burn patients across the U.S,” Dr Perry said.
The partnership comes shortly after AVITA had received FDA approval for its RECELL Autogenous Cell Harvesting Device.
The RECELL System is a device designed for the treatment of acute thermal burns.
It enables healthcare professional to produce a suspension of Spray-On Skin cells using a small sample of the patient’s own skin.
AVITA’s share price was up 5.25 per cent, trading at $3.21 per share by the end of the trading day.